YOUR VYZULTA TREATMENT GUIDE Please see Important Safety Information on pages 1, 9, 10, 17 and 18. Please see accompanying Prescribing Information.
INDICATION VYZULTA TM (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension. IMPORTANT SAFETY INFORMATION Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued. UNDERSTANDING GLAUCOMA WHAT IS OPEN-ANGLE GLAUCOMA? Open-angle glaucoma is a disease that gradually causes vision loss and may lead to blindness. It occurs when the fluid in one or both of your eyes does not drain properly. This increases the pressure in your eye, which may damage the optic nerve. EYE WITH GLAUCOMA Drainage Canal Blocked Increased Pressure Damage to the Optic Nerve While there is no way to reverse vision loss, early detection and treatment can help preserve sight. Please see additional Important Safety Information on pages 9, 10, 17 and 18. Please see accompanying Prescribing Information. 2
HOW MANY PEOPLE HAVE OPEN-ANGLE GLAUCOMA? Open-angle glaucoma is the most common form of glaucoma. Based on a 2013 estimate, more than 44 million people globally have open-angle glaucoma WHAT ARE THE SIGNS AND SYMPTOMS OF GLAUCOMA? Open-angle glaucoma does not have any early warning signs or symptoms. Over time, people with glaucoma will slowly begin to lose peripheral (side) vision. This can be hard to detect, so many people do not notice any vision changes until the disease has become more advanced. If left untreated, people with glaucoma may develop a visual disability and, eventually, blindness. Normal vision Vision with glaucoma While there is no cure for glaucoma and no way to reverse vision loss, early detection and treatment can help preserve sight. 4
UNDERSTANDING OCULAR HYPERTENSION WHAT IS OCULAR HYPERTENSION? Ocular hypertension is the medical term used when the pressure in the eye is higher than normal. It is caused when the fluid in the eye does not drain properly. OCULAR HYPERTENSION AND GLAUCOMA People with ocular hypertension may be at a higher risk of glaucoma and should be monitored carefully. Lowering eye pressure in people with glaucoma may slow or prevent vision loss. WHAT ARE THE SIGNS AND SYMPTOMS OF OCULAR HYPERTENSION? There are usually no signs or symptoms of ocular hypertension. It can be detected via routine testing by an eye care professional. It s important to remember to get your eyes tested by an eye care professional. Decreasing the pressure in the eye reduces the risk of vision loss from glaucoma. Please see Important Safety Information on pages 1, 9, 10, 17 and 18. Please see accompanying Prescribing Information. 6
WHAT IS VYZULTA? VYZULTA is a prostaglandin analog that may help reduce intraocular (eye) pressure in people with open-angle glaucoma or ocular hypertension. HOW DOES VYZULTA WORK? VYZULTA helps lower intraocular pressure by increasing drainage of fluid from the eye. It is believed to work through two different pathways in the eye. Lowering intraocular pressure can help reduce the risk of vision loss due to glaucoma. Please see Important Safety Information on pages 1, 9, 10, 17 and 18. Please see accompanying Prescribing Information. 8
POSSIBLE SIDE EFFECTS WHEN TO CALL YOUR DOCTOR The most common side effects seen in studies were eye redness, eye irritation, eye pain, and pain after putting the drops in your eye. These are not all of the possible side effects. INCREASED BROWN COLOR Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued. IMMEDIATELY SEEK YOUR DOCTOR S ADVICE CONCERNING THE CONTINUED USE OF VYZULTA IF YOU: Experience any change in your eye Have any eye condition that develops Experience any sudden change in your vision or any eye side effects Have eye surgery EYELASH CHANGES Gradual changes to eyelashes may occur, including increased length, thickness, color, number of eyelashes and/or direction of eyelash growth. These changes may result in a difference in appearance of each eye. These changes are usually reversible after VYZULTA treatment is discontinued. Please see additional Important Safety Information on pages 17 and 18. Please see accompanying Prescribing Information. 10
APPLYING YOUR EYE DROPS Step 1: Wash your hands. X HOW DO I ADMINISTER VYZULTA? VYZULTA should be used once daily at night. Do not administer VYZULTA more than once daily. IMPORTANT SAFETY INFORMATION Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions. The Pocket Step 2: Tilt your head back. Gently pull your lower eyelid down to form a pocket for the drop. Step 3: Administer one drop of VYZULTA into the pocket of the eye(s) with glaucoma. Step 4: Keep your eyes closed and gently press on the inner part of the eye for 30 seconds to keep VYZULTA in contact with the eye for longer. Please see additional Important Safety Information on pages 1, 9, 10, 17 and 18. Please see accompanying Prescribing Information. 12
COMMON ADMINISTRATION AND STORAGE QUESTIONS HOW DO I STORE VYZULTA? Store unopened bottles in a refrigerator. Once a bottle is opened, it may be stored at room temperature for up to eight weeks. Do not freeze bottles of VYZULTA. CAN I USE VYZULTA IF I WEAR CONTACT LENSES? If you wear contact lenses, remove them prior to administering VYZULTA. After administering VYZULTA, wait 15 minutes before reinserting your contact lenses. WHAT IF I USE OTHER EYE DROPS? If you are using other eye drops in addition to VYZULTA, wait 5 minutes between using each type of eye drop. Unopened refrigerated (36 F-46 F) Opened room temperature (36 F-77 F) Please see Important Safety Information on pages 1, 9, 10, 17 and 18. Please see accompanying Prescribing Information. 14
NOTES ACCESS PROGRAM Talk to your doctor about the cost savings program available for eligible patients from Bausch + Lomb * Learn how the Bausch + Lomb Access Program can help eligible patients save on your next prescription * * Terms and Conditions apply and can be found at www.bauschaccessprogram.com Please see Important Safety Information on pages 17 and 18. Please see accompanying Prescribing Information. 16
INDICATION VYZULTA TM (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension. IMPORTANT SAFETY INFORMATION Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued. Gradual changes to eyelashes may occur, including increased length, thickness, color, number of eyelashes and/or direction of eyelash growth. These changes may result in a difference in appearance of each eye. These changes are usually reversible after VYZULTA treatment is discontinued. IMPORTANT SAFETY INFORMATION (CONTINUED) Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions. Tell your doctor immediately about any change in your eye, any eye condition that develops, any sudden change in your vision, any eye side effects, or if you have eye surgery. Remove contact lenses before putting VYZULTA in your eyes. Lenses may be reinserted 15 minutes later. If you are using other eye drops in addition to VYZULTA, wait 5 minutes between using each type of eye drop. The most common side effects seen in studies were eye redness, eye irritation, eye pain, and pain after putting the drops in your eye. Please see accompanying Prescribing Information. 18
VYZULTA and the V design are trademarks of Bausch & Lomb Incorporated or its affiliates. 2017 Bausch & Lomb Incorporated. All rights reserved. VYZ.0069.USA.17